Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla® (apremilast) in Pivotal Phase 3 Psoriasis Study

PRINCETON, N.J.–(BUSINESS WIRE) November 3, 2020 — Bristol Myers Squibb (NYSE:BMY) today announced positive results from POETYK PSO-1, the first

Read more